Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-Targeted CAR-T in Advanced CEA-Positive Solid Tumors
NCT07179692Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of C-13-60 in lung cancer, gastric cancer (GC), colon cancer and 4 more (3 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety and Tolerability at 1 month and Recommended Dose and Infusion Regimen at 1 month. Started Sep 2025; status: recruiting.
02
Drugs
C-13-60
03
Conditions
lung cancergastric cancer (GC)colon cancerrectal canceresophageal cancer
Beyond the preview
Go deeper on NCT07179692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179692.